You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Biocatalytic production of precursors to lutein and zeaxanthin to address age related macular degeneration

    SBC: EscaZyme Biochemicals, LLC            Topic: N

    Project Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostl ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Evidence-Based Pain Intervention for Veterans: Leveraging Mobile and Social Media

    SBC: Pro-Change Behavior Systems Inc            Topic: NCCIH

    Chronic musculoskeletal pain creates a significant public health burden, and Veterans are disproportionately affected. The frequency and extent of co-occurrence of pain and PTSD, pain and Traumatic Brain Injury (TBI), all three conditions (Post-deployment Multi-symptom Disorder (PMD), and other multi-symptom syndromes can complicate and reduce the effectiveness of pain treatment. Furthermore, the ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease

    SBC: EPIVAX, INC.            Topic: 200

    ABSTRACT SignificanceGravesdiseaseGDone of the most prevalent autoimmune diseasesis caused by stimulating autoantibodiesTSAbto the Thyroid Stimulating Hormone ReceptorTSHRresulting in hyperthyroidismCurrent methods for managing hyperthyroidism in GD target excess thyroid hormone secretion by ablation or removal of the thyroid or by blocking thyroid hormone synthesisEach of these therapies is assoc ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Developing Testing and Validating a Wearable Alcohol Biosensor

    SBC: Clinitech, LLC            Topic: 450

    PROJECT SUMMARY This application for a Phase I SBIR award represents a collaboration between Clinitech LLC and McLean Hospital Harvard Medical School to develop a wearable biosensor for detecting alcohol in the interstitial fluid of humans who have consumed alcohol Excessive use of alcohol accounts for much of the public health burden related to alcohol use disorders including fetal ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, LLC            Topic: 105

    Neonatal hypoxia ischemiaHIremains a major cause of acute perinatal brain injuryleading ultimately to neurologic dysfunction manifesting as cerebral palsymental retardationand epilepsyUnfortunatelycurrent treatment and prevention strategies in newborns are limitedThere are no currently available therapies to prevent treat and or attenuate brain damage in premature infants other than supportive car ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. An Automated Platform for High-throughput Network Electrophysiology

    SBC: Calista Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Calista Therapeutics has discovered a first-in-class, proprietary PDZ1-2 lead drug, AT010, that is being optimized and developed as an inhaled daily therapy for cystic fibrosis (CF). CF is a deadly inherited genetic disorder that disrupts chloride channel function, resulting in the buildup of sticky mucus in patient's lungs and other organs.CF patients hav ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Developing an Improved Electrocompetent E. coli Host

    SBC: Pro-Change Behavior Systems Inc            Topic: NCATS

    DESCRIPTION (provided by applicant): Chronic musculoskeletal pain creates a significant public health burden. Veterans are disproportionately affected by chronic musculoskeletal pain, and in particular, chronic low back pain (CLBP). The frequency and extent of co-occurrence of pain and PTSD, pain and Traumatic Brain Injury (TBI), and all three conditions (Post-deployment Multi-symptom Disorder (PM ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Expediting the Production of High Value, Standardized, and Transparent Data

    SBC: MJ Datacorp, Ltd.            Topic: NCATS

    DESCRIPTION (provided by applicant): Researchers and contractors are under increasing pressure to produce rapid turnaround times for data releases and publications. Inadequate data management is a common threat to good research and impedes the quick release of high value data. Despite its importance, many organizations do not have standardized data management practices that allow them to prepare h ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government